Thus, the goal of the present review was to systematically review the published empirical literature and qualitatively synthesize existing evidence that either pharmacological or genetic manipulation/variation of FAAH, MAGL, and DAGL might impact obesity-related outcomes. The gene discussed is FAAH; the disease is obesity due to melanocortin 4 receptor deficiency.